USPTO serial 76350957
SCIENION
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 10, 2006
- Examiner
- MCMORROW, RONALD G
- Law office
- GENERIC WEB UPDATE
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SCIENION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $3,400
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
12489 Berlin, DE
12489 Berlin, DE
12489 Berlin, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Brown
Jeffrey H. Brown Michael Best & Friedrich LLP444 West Lake Street, Suite 3200Chicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for industrial and scientific purposes, namely, nucloic acids, peptides and proteins for scientific and research use in the fields of phannacology, foodstuffs, plant protection, cosmetics, diagnostics and biochemical and medical research; libraries of immobilized chemical compounds for scientific and research use in the fields of pharmacology, foodstuffs, plant protection, cosmetics, diagnostics and biochemical and medical research; arrays of chemical compounds, namely, nucleic acids, peptides and proteins for scientific and research use in the fields of pharmacology, foodstuffs, plant protection, cosmetics, diagnostics and biochemical and medical research; arrays of libraries of chemical compounds arranged on a support for scientific and research use in the fields of pharmacology, foodstuffs, plant protection, cosmetics, diagnostics and biochemical and medical research; chemical compounds produced by using immobilized chemical compounds, libraries of chemical compounds and arrays of chemical compounds, namely, such compounds which are immobilized on a support for scientific and research use in the fields of pharmacology, foodstuffs, plant protection, cosmetics, diagnostics and biochemical and medical research | ACTIVE | — |
| 005 | [ Pharmaceutical and veterinary products, namely, antiseptics, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic and antihypoxaemics; analgesics and antirheumatic drags, pharmaceuticals functioning as antihelmintics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antiinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolyrics, hemostatics, antihypertonics, antihypoglycemics, antihypotonica, anlicoagulauts, antimycotics, pharmaceuticals functioning as antiparasitics, antiphiogistics, antitussives, expectorants for use in atherosclerosis, balneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensin system, pharmaceuticals functioning as broncholytics, antiasthmetics cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disirifectants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; diagnostic preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anesthetics, neural therapeutics, gastro-ititestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye, chalazion, dacryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use in osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinositic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologics and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; homeopathic remedies for use in the treatment of salmonellosis, paratuberculosis and cancer; veterinary preparations for use in the treatment of diseases equivalent to salnionellosis, paratubeculosis and cancer; pharmaceutical and veterinary products, namely, antiseptics, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic and antihypoxaemics; analgesics and antirhsuinatic drugs, pharmaceuticals functioning as antihelmintics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antlinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics; antiepileptics, antihermorrhagics, antifibrinolyrics, hemostatic; antihypertonics, antihypoglycomics, antihypotonica, anticoagulant; antimycotics, pharmaceuticals functioning as antiparasitics, antiphiogistics, antitussives, expectorants for use in atherosclerosis, balneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensinir system, pharmaceuticals functioning as broncholytics, antiastlimetics cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disinfeetants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; diagnostic preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anesthetics, neural therapeutics, gastro- intestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye, chalazion, daoryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use in osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinositic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologica and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; homeopathic remedies far use in the treatment of salmonellosis, paratubereulosis and cancer; arrays of libraries of chemical compounds arranged on a support for clinical or medical laboratory use; chemical compounds arranged on a support for clinical or medical laboratory use; nutraceuticals for use in dietary supplements ] | SECTION 8 - CANCELLED | — |
| 009 | Scientific measure and controlling apparatus and instruments; support materials, more particularly membranes and glass; scientific instruments and devices comprising support materials, more particularly membranes and glass, comprising chemical products for industrial and scientific purposes, more particularly nucleic acids, peptides and proteins, comprising immobilized chemical compounds, comprising libraries of chemical compounds for industrial and scientific purposes, more particularly immobilized chemical compounds for industrial and scientific purposes, comprising arrays of chemical compounds, more particularly of nucleic acids, peptides and proteins, comprising arrays of libraries of chemical compounds, more particularly libraries of chemical compounds arranged on a support, comprising compounds produced by using or by means of immobilized chemical compounds, libraries of chemical compounds or arrays of chemical compounds, more particularly such chemical compounds which are immobilized on a support, comprising chemical compounds for industrial and scientific purposes manufactured by using or by means of chemical products for industrial and scientific purposes, more particularly nucleic acids, peptides and proteins; computer software and programs, more particularly computer programs for synthesis and/or immobilization of chemical products for industrial and scientific purposes, more particularly nucleic acids, peptides and proteins, of immobilized chemical compounds, of arrays of libraries of chemical compounds, more particularly arrays of chemical compounds arranged on a support, of compounds manufactured with the aid of immobilized chemical compounds, libraries of chemical compounds or arrays of chemical compounds, more particularly such compounds which are immobilized on a support; computer software (saved), computer programs, more particularly computer programs for analysis of patterns of surfaces, more particularly of support materials like membranes and glass, more particularly such supports comprising chemical products for industrial and scientific purposes, more particularly nucleic acids, peptides and proteins, for analysis of immobilized chemical compounds, for analysis of chemical compounds for industrial and scientific purposes, for analysis of arrays of chemical compounds, more particularly of nucleic acids, peptides and proteins, for analysis of arrays of libraries of chemical compounds, more particularly libraries of chemical compounds arranged on a support, for analysis of compounds manufactured with the aid of immobilized chemical compounds, libraries of chemical compounds or arrays of chemical compounds, more particularly such compounds which are immobilized on a support; programs, more particularly computer programs, for screening of compounds such as nucleic acids, peptides and proteins; software for picture evaluation; and software for data evaluation; apparatus and apparatus for analysis for use in synthesis and/or immobilization of chemical products for industrial and scientific purposes, for production and analysis of patterns of surfaces and for screening of compounds such as nucleic acids, peptides and proteins, more particularly such apparatus and apparatus for analysis with integrated data analysis; diagnostic apparatus and analysis apparatus for synthesis and/or immobilization of chemical products for industrial and scientific purposes, for production and analysis of patterns of/on surfaces and for screening of compounds such as nucleic acids, peptides and proteins, more particularly such apparatus and analysis apparatus with integrated data analysis; chambers, more particularly chambers for hybridization; spotting apparatus | ACTIVE | — |
| 040 | Custom chemical synthesis for others, namely, synthesis of nucleic acids, peptides, and proteins for industrial and scientific purposes, synthesis of immobilized chemical compounds, arrays, and libraries of nucleic acids, peptides and proteins for industrial and scientific purposes; immobilization of chemical products for others, namely, immobilization of nucleic acids, peptides, and proteins for industrial and scientific purposes, immobilization of arrays and libraries of nucleic acids, peptides and proteins for industrial and scientific purposes; custom manufacture, spotting, and design of biochips for others | ACTIVE | — |
| 042 | Product research and development in the fields in the fields of biology, biochemistry, chemistry, medicine, veterinary medicine, pharmacology, genetics, cytogenetics, molecular biology, and biotechnology, namely, products used in the synthesis and immobilization of chemical products for industrial and scientific purposes, products research and development in the field of synthesis and immobilization of arrays and arrays of libraries of chemical compounds arranged on a support; scientific research, namely, screening for chemical interaction partners; product research and development in the field of chemical screening for interaction partners; development of new diagnostic technology for others in the fields of biology, biochemistry, chemistry, medicine, veterinary medicine, pharmacology, genetics, cytogenetics, molecular biology, and biotechnology; screening and development of arrays and libraries of arrays of immobilized chemical compounds arranged on a support for industrial and scientific purposes; development of computer software for use in screening and development of arrays and libraries of arrays of immobilized chemical compounds arranged on a support for industrial and scientific purposes; development of data processing software for use in product research and screening; database development and providing an on-line database in the field of product research and development in the fields of biology, biochemistry, chemistry, medicine, veterinary medicine, pharmacology, genetics, cytogenetics, molecular biology, and biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Scienion AG
- Other trademarks owned by Scienion AG
- Other trademarks owned by Scienion AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named SCIENION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 10, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 5, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 13, 2017 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jan 13, 2017 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jan 13, 2017 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jan 10, 2017 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Sep 7, 2016 | PR89 | POST REGISTRATION ACTION MAILED - SEC. 8 & 9 | — |
| Sep 6, 2016 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Oct 10, 2015 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Mar 15, 2013 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Mar 15, 2013 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 15, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 1, 2013 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Mar 1, 2013 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 22, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 3, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2007 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Oct 19, 2007 | PAPER RECEIVED | — | |
| Oct 10, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 25, 2006 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Aug 25, 2006 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Aug 8, 2006 | PAPER RECEIVED | — | |
| Mar 6, 2006 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 6, 2006 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 6, 2006 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 21, 2005 | UNDN | UNDELIVERABLE MAIL - NO ACTION TAKEN | — |
| Dec 6, 2005 | PAPER RECEIVED | — | |
| Dec 1, 2005 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 16, 2005 | PETG | PETITION TO REVIVE-GRANTED | — |
| Oct 4, 2005 | PETR | PETITION TO REVIVE-RECEIVED | — |
| Oct 4, 2005 | PAPER RECEIVED | — | |
| Sep 22, 2005 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 22, 2005 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 28, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 8, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 19, 2004 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 8, 2004 | ALIE | ASSIGNED TO LIE | — |
| Oct 6, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 3, 2004 | PAPER RECEIVED | — | |
| Jun 18, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 18, 2004 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Jun 18, 2004 | PAPER RECEIVED | — | |
| Feb 4, 2004 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 18, 2003 | CFIT | CASE FILE IN TICRS | — |
| Nov 24, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 24, 2003 | PAPER RECEIVED | — | |
| May 22, 2003 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Nov 7, 2002 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Sep 27, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 28, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2002 | DOCK | ASSIGNED TO EXAMINER | — |